LFG
ARQT icon

Larson Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Larson Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75K Buy
143
+11
+8% +$256 ﹤0.01% 2885
2026
Q1 		$3.11K Sell
132
-85
-39% -$2.17K ﹤0.01% 2811
2025
Q4 		$6.3K Buy
217
+31
+17% +$794 ﹤0.01% 2366
2025
Q3 		$3.51K Sell
186
-1,603
-90% -$25.3K ﹤0.01% 2490
2025
Q2 		$25.1K Buy
1,789
+662
+59% +$9.28K ﹤0.01% 1370
2025
Q1 		$17.6K Buy
+1,127
New +$15.9K ﹤0.01% 1410

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Larson Financial Group's ARQT Position: Q2 2026 in Review

Larson Financial Group increased its Arcutis Biotherapeutics (ARQT) stake by 8.3% in Q2 2026, buying an estimated $256 and bringing the position to 143 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #2885.

Larson Financial Group first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $25.1K in Q2 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Larson Financial Group held 143 shares of Arcutis Biotherapeutics worth $3.75K as of Q2 2026.
  • Larson Financial Group bought 11 Arcutis Biotherapeutics shares in Q2 2026, an estimated $256.
  • Arcutis Biotherapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2885 holding.
  • Larson Financial Group first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • Larson Financial Group's Arcutis Biotherapeutics position peaked at $25.1K in Q2 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.